NATH BIOGENES (INDIA)
Back to Balance Sheet
|
NATH BIOGENES (INDIA) Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2013 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹365 Cr | ₹262 Cr | ₹216 Cr | ₹194 Cr | ₹98 Cr |
What is the latest Total Current Liabilities ratio of NATH BIOGENES (INDIA) ?
| Year | Total Current Liabilities |
|---|---|
| Mar2025 | ₹365 Cr |
| Mar2024 | ₹262 Cr |
| Mar2023 | ₹216 Cr |
| Mar2022 | ₹194 Cr |
| Mar2013 | ₹98 Cr |
How is Total Current Liabilities of NATH BIOGENES (INDIA) Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹365 Cr | 39.19 | |
| Mar2024 | ₹262 Cr | 21.26 | |
| Mar2023 | ₹216 Cr | 11.40 | |
| Mar2022 | ₹194 Cr | 98.02 | |
| Mar2013 | ₹98 Cr | - | |
Compare Total Current Liabilities of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹327.2 Cr | 19.3% | 16% | -5.8% | Stock Analytics | |
| BOMBAY BURMAH TRADING CORPORATION | ₹10,134.7 Cr | 1.4% | -7% | -15.8% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,768.7 Cr | 6.9% | 14.9% | -36.5% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,083.2 Cr | 8.1% | 13.8% | -10.6% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹1,061.8 Cr | -9.8% | 20.4% | -20.4% | Stock Analytics | |
| INDO US BIOTECH | ₹213.8 Cr | 2.3% | 6% | -33.4% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | 19.3% |
16% |
-5.8% |
| SENSEX | 3.7% |
-0.9% |
0.7% |
You may also like the below Video Courses